Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab

Denosumab, a fully human monoclonal antibody, has been approved for the treatment of postmenopausal osteoporosis. The therapeutic effect of denosumab rests on its ability to inhibit osteoclast differentiation. Here, we present a computational approach on the basis of coupling a pharmacokinetics mode...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheiner, S, Pivonka, P, Smith, D W, Dunstan, C R, Hellmich, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Paper Presented at Eccomas-3MBM - Multiscale and Multiphysics Modelling in Bone Mechanobiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4291103/
https://www.ncbi.nlm.nih.gov/pubmed/24039120
http://dx.doi.org/10.1002/cnm.2584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4291103/
https://www.ncbi.nlm.nih.gov/pubmed/24039120
http://dx.doi.org/10.1002/cnm.2584

Ejemplares similares